Patients with inoperable, advanced HER2-positive bile duct cancer
Study objective:
Efficacy and safety of zanidatamab in combination with standard therapy compared to standard therapy
Contact person:
Professor Dr. Michael Quante
TRAP-BTC
Target group:
Patients with untreated, unresectable & HER2-positive cholangiocarcinoma or gallbladder carcinoma
Study objective:
The primary objective of this study is to evaluate the efficacy of the combination of standard of care treatment using GemCis in combination with trastuzumab and pembrolizumab in terms of treatment response rate at 6 months.
Contact person:
Professor Dr. Michael Quante
CARP
Target group:
Patients with cholangiocarcinoma (bile duct cancer)
Study objective:
Treatment of cholangiocarcinoma with radiofrequency ablation or photodynamic therapy and investigation of side effects and quality of life
Contact person:
Dr. Armin Küllmer
DESTINY-Biliary Tract Cancer-01 D781PC00001
Target group:
Untreated patients with locally advanced or metastatic HER2-positive bile duct cancer
Study objective:
To evaluate the efficacy of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in combination with the antibody rilvegostomig as first-line therapy. The aim is to determine the overall survival time compared to standard therapy.
Contact person:
Prof. Dr. Michael Quante
FIRE-8
Target group:
Patients with histologically confirmed adenocarcinoma of the colon or rectum
Study objective:
Comparison of the efficacy of treatment with trifluridine/tipiracil plus panitumumab with that of trifluridine/tipiracil plus bevacizumab (nucleoside analogs in comparison with various approved antibodies)
Contact person:
Professor Dr. Michael Quante
FIRE-9
Target group:
Patients with colorectal carcinoma and resected primary tumor
